Cancer
Roche’s Tecentriq falls short as an adjuvant monotherapy in muscle-invasive urothelial cancer
January 24, 2020Medical Communications, Sales and Marketing Cancer, Roche, pharma, tecentriq, trial failure
Roche has released an update on the development of its immunology Tecentriq (atezolizumab), making it known that the drug failed …
EU approval for Roche’s Polivy combo in relapsed/refractory B-cell lymphoma
January 21, 2020Manufacturing and Production, Sales and Marketing Cancer, Polivy, Roche, lymphoma, pharma
The European Commission has awarded conditional marketing approval to Roche’s Polivy (polatuzumab vedotin), it has been revealed.
Cardiff University team discovers new method of killing cancers
January 21, 2020Manufacturing and Production Cancer, Cancer cures, Cancerous, Cardiff University, T cell, cells, immune system, immunity, t-cell
A team at Cardiff University have discovered a new part of the human immune system that could be harnessed to …
Lynparza secures accelerated FDA review for metastatic castration-resistant prostate cancer
January 20, 2020Sales and Marketing Cancer, FDA, lynparza, pharma
Following the recommendation of the tablet formulation of the drug for use on the NHS in England and Wales, news …
NICE turns down Bayer’s tumour-agnostic therapy Vitrakvi over evidence concerns
January 20, 2020Sales and Marketing Bayer, Cancer, NICE, Vitravki
UK drug watchdog NICE has turned down Bayer’s Vitrakvi (larotrectinib) as a tumour-agnostic treatment solution on the NHS after it …
NICE shoots down Keytruda in head and neck cancer over data concerns
January 16, 2020Sales and Marketing Cancer, NHS, NICE, UK, keytruda, pharma
It has been revealed that NICE has chosen to reject MSD’s blockbuster immunotherapy Keytruda (pembrolizumab) for routine use on the …
NHS Scotland recommends Janssen’s Zytiga combo for newly diagnosed prostate cancer
January 13, 2020Sales and Marketing Cancer, NHS, Scotland, nhs scotland, prostate cancer
Janssen’s Zytiga (abiraterone acetate) has just been approved by the Scottish Medicines Consortium (SMC), meaning that male patients on the …
US approval for Blueprint Medicines’ gastrointestinal stromal tumour therapy
January 10, 2020Medical Communications, Sales and Marketing Ayvakit, Blueprint Medicines, Cancer, pharma
The FDA has moved to authorise Blueprint Medicines’ kinase inhibitor Ayvakit (avapritinib) for the treatment of unresectable or metastatic gastrointestinal …
MSD’s Keytruda chalks up bladder cancer approval in the US
January 9, 2020Sales and Marketing Cancer, MSD, bladder cancer, keytruda, pharma
MSD’s blockbuster immunotherapy Keytruda (pembrolizumab) has added another US approval to its repertoire with the news that FDA has awarded …
Largest drop ever in US cancer mortality rates, new study shows
January 9, 2020Business Services Cancer, brain cancer, lung cancer, prostate cancer
The overall cancer mortality rate in the US fell by 2.2% from 2016 to 2017, the largest ever annual decline …
Single cycle of chemo is just as effective as two in treating testicular cancer, study finds
January 3, 2020Medical Communications Cancer, Men's Cancer, chemo, chemotherapy, testicular cancer
A new study shows that testicular cancer can be successfully treated with less rounds of chemotherapy. The recent study, published …
AI is more accurate than doctors at diagnosing breast cancer, study finds
January 2, 2020Business Services AI, AI Cancer, AI Trials, AI diagnoses, AI in clinical trials, Cancer, breast cancer
A recent study showed that Artificial Intelligence is more accurate than doctors in diagnosing breast cancer from mammograms. The research …
FDA gives accelerated approval to AstraZeneca and Daiichi’s breast cancer drug
December 23, 2019Sales and Marketing AstraZeneca, Breast Cancer drug, Cancer, breast cancer, skin cancer
The FDA has approved the breast cancer drug Enhertu, developed by AstraZeneca and Daiichi Sankyo. José Basel, the Executive Vice …
AstraZeneca sells Amrimidx and Casodex European rights to Juvisé Pharmaceuticals
December 20, 2019Medical Communications AstraZeneca, Cancer, Juvise, breast cancer, prostate cancer
AstraZeneca has announced that it has agreed to sell the rights to Arimidex (anastrozole) and Casodex (bicalutamide) in Europe, as …
FDA approves Seattle Genetics and Astellas Pharma’s bladder cancer drug
December 19, 2019Business Services Astellas Pharma, Cancer, Padcev, Seattle Genetics, bladder cancer
The FDA has granted accelerated approval for Seattle Genetics and Astellas Pharma’s bladder cancer drug Padcev (enfortumab vedotin-ejfv). The drug’s …
Latest content
ESTEVE CDMO adds $17.5m to Illinois expansion
Brenntag and dsm-firmenich expand biopharma vitamin partnership
